Presentation: 4:00-5:00pm
Discussion & Reception: 5:00-6:00pm

Colin J. Meyer, MD, MBA, Director of Product Development
Paul Foster, MD, Chief Medical Officer, VP Clinical Development and Regulatory Affairs
Leslie Lescale-Matys, Director of Clinical Programs

Topics/Products Presented:

• RTA 402: A Suppresser of Tumor and Treatment Associated Inflammation through Inhibition of  NF-kB and STAT3
• RTA 744: Novel antrhacycline derivate (crosses blood-brain barrier
• Update on pre-clinical efforts
  
• p53 Protein Misfolding Array (Identification of small molecule chaperones that prevent or reverse p53 misfolding)

Note: Presentations are designated for the Harvard Research community only and are not open to the public.

For more information, or if you would like to schedule a 1:1 meeting with Reata during the afternoon of April 19, please e-mail Olga Benitez or contact by phone at 617-724-3867.